latest update:
[TrialBase DB]

trial summary · NCT07551596

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Colorectal Adenocarcinoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07551596phase PHASE2enrollment 20start 2027-05-25

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the blood. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab may be an effective combination to remove any remaining microscopic cancer cells in the bloodstream in patients with stage II/III colorectal adenocarcinoma. In addition, clearing the ctDNA from the blood may serve as an early indicator of treatment response.

Source record: https://clinicaltrials.gov/study/NCT07551596

Facts

registry idNCT07551596
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionColorectal Adenocarcinoma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment20
start date2027-05-25
primary completion2029-08-28
completion2029-08-28
results postednot reported

Conditions

  • Colorectal Adenocarcinoma
  • Stage II Colorectal Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8

Interventions

  • Balstilimab
  • Biopsy Procedure
  • Biospecimen Collection
  • Botensilimab
  • Radiographic Examination

Countries

  • United States

Intervention types: BIOLOGICAL, PROCEDURE

Work with this record